Persistent Asset Partners Ltd Acquires New Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Key Points

• Persistent Asset Partners Ltd has acquired a new stake in GoodRx Holdings, Inc., purchasing 101,755 shares for approximately $449,000.
• Major shareholder Equity Vii L.P. Spectrum sold 10,677 shares at an average price of $4.80, totaling around $51,250, while insiders collectively own 4.17% of the stock.
• GoodRx's shares have faced recent downgrades from multiple analysts, with Goldman Sachs reducing their price objective from $6.00 to $5.00 and assigning a "neutral" rating.

Persistent Asset Partners Ltd acquired a new stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 101,755 shares of the company's stock, valued at approximately $449,000.

A number of other hedge funds have also made changes to their positions in GDRX. Hohimer Wealth Management LLC grew its position in GoodRx by 8.2% in the first quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company's stock worth $155,000 after buying an additional 2,658 shares during the last quarter. SBI Securities Co. Ltd. grew its position in GoodRx by 13.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company's stock worth $100,000 after purchasing an additional 2,748 shares in the last quarter. Gotham Asset Management LLC grew its position in GoodRx by 31.0% during the 4th quarter. Gotham Asset Management LLC now owns 17,677 shares of the company's stock worth $82,000 after purchasing an additional 4,182 shares in the last quarter. Citizens Financial Group Inc. RI purchased a new position in GoodRx during the 1st quarter worth approximately $44,000. Finally, Headlands Technologies LLC grew its position in GoodRx by 213.2% during the 1st quarter. Headlands Technologies LLC now owns 14,830 shares of the company's stock worth $65,000 after purchasing an additional 10,095 shares in the last quarter. Institutional investors and hedge funds own 63.77% of the company's stock.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 4.17% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

GDRX has been the topic of several research analyst reports. The Goldman Sachs Group lowered their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Raymond James Financial cut shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a report on Friday. Wells Fargo & Company decreased their price objective on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. UBS Group decreased their price objective on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $6.00 price objective on shares of GoodRx in a report on Monday. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, GoodRx presently has an average rating of "Moderate Buy" and an average price target of $6.18.

GoodRx Trading Up 0.3%

Shares of NASDAQ GDRX opened at $3.48 on Tuesday. The company's fifty day moving average is $4.60 and its 200-day moving average is $4.54. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of 34.80, a P/E/G ratio of 1.37 and a beta of 1.24. GoodRx Holdings, Inc. has a twelve month low of $3.31 and a twelve month high of $8.80. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.75.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The company had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. During the same period in the prior year, the firm posted $0.08 earnings per share. The company's revenue was up 1.2% compared to the same quarter last year. Equities research analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

Want to see what other hedge funds are holding GDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.